ANI Pharmaceuticals
ANIP
173 hedge funds and large institutions have $424M invested in ANI Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 66 increasing their positions, 53 reducing their positions, and 28 closing their positions.
28% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $2.3M
25% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 53
2.46% more ownership
Funds ownership: 60.99% → 63.45% (+2.5%)
6% less funds holding
Funds holding: 184 → 173 (-11)
12% less capital invested
Capital invested by funds: $480M → $424M (-$56.5M)
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$7.07M |
| 2 |
First Manhattan
New York
|
+$4.28M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.52M |
| 4 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$3.37M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.28M |
Top Sellers
| 1 |
AIA
Avalon Investment & Advisory
Houston,
Texas
|
-$3.22M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$3.14M |
| 3 |
Morgan Stanley
New York
|
-$2.53M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$2.03M |
| 5 |
MSL
Mackay Shields LLC
New York
|
-$1.95M |
ANIP Hedge Fund Activity: Q3 2018 in Review
173 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2018, worth a combined $424M — down 12% from $480M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ANIP and 19 opened new positions — a net loss of 9 holders — while 53 trimmed existing stakes and 66 added.
The largest buyer was Mangrove Partners, adding an estimated $7.07M. The largest seller was Avalon Investment & Advisory, exiting entirely with an estimated $3.22M sold.
- 173 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2018, down from 184 in Q2 2018.
- Funds reported $424M of ANI Pharmaceuticals stock for Q3 2018, down 12% quarter-over-quarter.
- 19 funds opened new ANI Pharmaceuticals positions in Q3 2018 and 28 closed out, a net change of -9 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2018 was Mangrove Partners, an estimated $7.07M added.
- The largest ANI Pharmaceuticals seller in Q3 2018 was Avalon Investment & Advisory, an estimated $3.22M sold.
Based on aggregated 13F filings for Q3 2018.